4D Molecular Therapeutics’ (FDMT) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) in a report issued on Monday, MarketBeat.com reports. They currently have a $36.00 price objective on the stock.

FDMT has been the topic of a number of other reports. Jefferies Financial Group reaffirmed a “buy” rating and issued a $21.00 price target (down from $40.00) on shares of 4D Molecular Therapeutics in a research note on Monday, March 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Friday, July 17th. Wall Street Zen cut shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, The Goldman Sachs Group set a $33.00 target price on shares of 4D Molecular Therapeutics in a research note on Friday, May 8th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, 4D Molecular Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $29.88.

4D Molecular Therapeutics Stock Down 3.7%

NASDAQ FDMT opened at $10.96 on Monday. The company has a 50-day simple moving average of $10.40 and a two-hundred day simple moving average of $9.53. 4D Molecular Therapeutics has a 12-month low of $4.27 and a 12-month high of $14.00. The firm has a market cap of $572.99 million, a price-to-earnings ratio of -4.26 and a beta of 2.70.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its earnings results on Thursday, May 7th. The company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). The company had revenue of $3.05 million during the quarter, compared to the consensus estimate of $2.59 million. 4D Molecular Therapeutics had a negative net margin of 182.34% and a negative return on equity of 36.83%. Equities analysts expect that 4D Molecular Therapeutics will post -3.8 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Scott Bizily sold 9,810 shares of the business’s stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $12.00, for a total transaction of $117,720.00. Following the transaction, the insider owned 8,617 shares in the company, valued at $103,404. The trade was a 53.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider David Kirn sold 15,725 shares of the company’s stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $12.03, for a total value of $189,171.75. Following the transaction, the insider directly owned 884,152 shares of the company’s stock, valued at $10,636,348.56. The trade was a 1.75% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 184,811 shares of company stock worth $2,075,906 over the last three months. 7.90% of the stock is owned by insiders.

Hedge Funds Weigh In On 4D Molecular Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in FDMT. Wexford Capital LP bought a new stake in 4D Molecular Therapeutics in the third quarter valued at $41,000. Daiwa Securities Group Inc. raised its holdings in 4D Molecular Therapeutics by 3,362.0% in the 4th quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company’s stock worth $48,000 after purchasing an additional 6,186 shares in the last quarter. Susquehanna Portfolio Strategies LLC purchased a new stake in shares of 4D Molecular Therapeutics in the 4th quarter worth about $77,000. Martingale Asset Management L P boosted its stake in shares of 4D Molecular Therapeutics by 12.4% during the 4th quarter. Martingale Asset Management L P now owns 11,775 shares of the company’s stock valued at $88,000 after purchasing an additional 1,303 shares in the last quarter. Finally, Gabelli Funds LLC bought a new stake in shares of 4D Molecular Therapeutics during the 4th quarter valued at about $90,000. Institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.